



## Xgeva<sup>®</sup> (denosumab) – New warning

- On January 24, 2018, the [FDA approved](#) an update to the *Warnings and Precautions* section of the [Xgeva \(denosumab\)](#) drug label regarding multiple vertebral fractures (MVF) following treatment discontinuation.
- Xgeva is indicated for the following:
  - Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
  - Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  - Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
- MVF have been reported following discontinuation of treatment with denosumab.
  - Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or prior fractures.
  - When Xgeva treatment is discontinued, evaluate the individual patient's risk for vertebral fractures.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.